Tag: Michael Baker
Arovella’s ALA-101 inches toward clinic following key manufacturing achievement
Arovella Therapeutics Ltd, the biotechnology company specialising in iNKT cell therapy, announced that the Good Manufacturing Practice (GMP)-grade lentiviral vector for its lead product, ALA-101, has completed successful manufacturing and quality release testing.
Featured Article
Smarter energy decisions: GridBeyond unveils AI-powered Bid Optimiser in Australia
As Australia’s energy transition accelerates, businesses participating in the National Electricity Market (NEM) are facing growing challenges in managing their energy assets efficiently.
